---
reference_id: "PMID:41544627"
title: Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma.
authors:
- Bernardi F
- Torrejon J
- Basili I
- Van Ommeren R
- Marsaud V
- Yu H
- Talbot J
- Souphron J
- Indersie E
- Forget A
- Bonneau B
- Massiot A
- Alcazar C
- Figeac L
- Bonerandi E
- Cancila G
- Sirbu O
- Yadav N
- Mohanakrishnan D
- Lombard B
- Loew D
- Poullet P
- Liva S
- Lovino M
- Lin IH
- Nakashima T
- Gharsalli T
- Nicolas PA
- Yubuki N
- Ribas RA
- Colsch B
- Chu-Van E
- Castelli F
- Sampaio JL
- Leboucher S
- Lasgi C
- Besse L
- Soler MN
- Lo Re V
- Planque N
- Abeysundara N
- Balin P
- Wang H
- Su H
- Wu X
- Cavalli FMG
- Saulnier O
- Ficarra E
- Di Marcotullio L
- Kumegawa K
- Maruyama R
- Kawauchi D
- Picard D
- Remke M
- Riffaud L
- Puiseux C
- Bouchoucha Y
- Huybrechts S
- Simbozel M
- Bourdeaut F
- Varlet P
- Puget S
- Blauwblomme T
- Andrianteranagna M
- Planchon JM
- Dugourd A
- Saez-Rodriguez J
- Barillot E
- Servant N
- Martignetti L
- Rich J
- Kool M
- Pfister SM
- Agnihotri S
- Suzuki H
- Fanjul M
- Wang WJ
- Tsai JW
- Sun RC
- Beccaria K
- Dufour C
- Sarry JE
- Michealraj KA
- Taylor MD
- Ayrault O
journal: Cancer Cell
year: '2026'
doi: 10.1016/j.ccell.2025.12.012
content_type: abstract_only
---

# Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma.
**Authors:** Bernardi F, Torrejon J, Basili I, Van Ommeren R, Marsaud V, Yu H, Talbot J, Souphron J, Indersie E, Forget A, Bonneau B, Massiot A, Alcazar C, Figeac L, Bonerandi E, Cancila G, Sirbu O, Yadav N, Mohanakrishnan D, Lombard B, Loew D, Poullet P, Liva S, Lovino M, Lin IH, Nakashima T, Gharsalli T, Nicolas PA, Yubuki N, Ribas RA, Colsch B, Chu-Van E, Castelli F, Sampaio JL, Leboucher S, Lasgi C, Besse L, Soler MN, Lo Re V, Planque N, Abeysundara N, Balin P, Wang H, Su H, Wu X, Cavalli FMG, Saulnier O, Ficarra E, Di Marcotullio L, Kumegawa K, Maruyama R, Kawauchi D, Picard D, Remke M, Riffaud L, Puiseux C, Bouchoucha Y, Huybrechts S, Simbozel M, Bourdeaut F, Varlet P, Puget S, Blauwblomme T, Andrianteranagna M, Planchon JM, Dugourd A, Saez-Rodriguez J, Barillot E, Servant N, Martignetti L, Rich J, Kool M, Pfister SM, Agnihotri S, Suzuki H, Fanjul M, Wang WJ, Tsai JW, Sun RC, Beccaria K, Dufour C, Sarry JE, Michealraj KA, Taylor MD, Ayrault O
**Journal:** Cancer Cell (2026)
**DOI:** [10.1016/j.ccell.2025.12.012](https://doi.org/10.1016/j.ccell.2025.12.012)

## Content

1. Cancer Cell. 2026 Jan 15:S1535-6108(25)00546-X. doi: 
10.1016/j.ccell.2025.12.012. Online ahead of print.

Multiomic integration reveals tumoral heterogeneity of lipid dependence within 
lethal group 3 medulloblastoma.

Bernardi F(1), Torrejon J(1), Basili I(2), Van Ommeren R(3), Marsaud V(4), Yu 
H(4), Talbot J(1), Souphron J(1), Indersie E(4), Forget A(4), Bonneau B(5), 
Massiot A(1), Alcazar C(6), Figeac L(1), Bonerandi E(1), Cancila G(4), Sirbu 
O(7), Yadav N(8), Mohanakrishnan D(8), Lombard B(9), Loew D(9), Poullet P(10), 
Liva S(10), Lovino M(11), Lin IH(12), Nakashima T(13), Gharsalli T(14), Nicolas 
PA(10), Yubuki N(15), Ribas RA(16), Colsch B(17), Chu-Van E(17), Castelli F(17), 
Sampaio JL(18), Leboucher S(19), Lasgi C(20), Besse L(15), Soler MN(15), Lo Re 
V(1), Planque N(21), Abeysundara N(22), Balin P(23), Wang H(22), Su H(23), Wu 
X(23), Cavalli FMG(10), Saulnier O(24), Ficarra E(11), Di Marcotullio L(25), 
Kumegawa K(26), Maruyama R(27), Kawauchi D(28), Picard D(29), Remke M(29), 
Riffaud L(30), Puiseux C(31), Bouchoucha Y(32), Huybrechts S(33), Simbozel 
M(34), Bourdeaut F(35), Varlet P(36), Puget S(37), Blauwblomme T(37), 
Andrianteranagna M(10), Planchon JM(38), Dugourd A(39), Saez-Rodriguez J(40), 
Barillot E(10), Servant N(10), Martignetti L(10), Rich J(41), Kool M(42), 
Pfister SM(43), Agnihotri S(44), Suzuki H(13), Fanjul M(45), Wang WJ(12), Tsai 
JW(46), Sun RC(16), Beccaria K(37), Dufour C(47), Sarry JE(48), Michealraj 
KA(49), Taylor MD(50), Ayrault O(51).

Author information:
(1)Institut Curie, PSL Research University, INSERM U1330/CNRS EMR 8001, 
Children's Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, 
Paris, France; Université Paris-Saclay, INSERM U1330/CNRS EMR 8001, Children's 
Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, Orsay, France.
(2)Institut Curie, PSL Research University, INSERM U1330/CNRS EMR 8001, 
Children's Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, 
Paris, France; Université Paris-Saclay, INSERM U1330/CNRS EMR 8001, Children's 
Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, Orsay, France; 
Istituto Pasteur-Fondazione Cenci Bolognetti, University of Rome La Sapienza, 
00161, Rome, Italy.
(3)Developmental and Stem Cell Biology Program, The Hospital for Sick Children, 
Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, 
The Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory 
Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
(4)Institut Curie, PSL Research University, Orsay, France; CNRS UMR 3347, INSERM 
U1021, Université Paris-Saclay, Orsay, France.
(5)Université Paris-Saclay, INSERM U1330/CNRS EMR 8001, Children's Oncology 
Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, Orsay, France.
(6)Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, 
Inserm, CNRS, Equipe Labellisée LIGUE 2023, Toulouse, France; Labex TOuCAN, 
Toulouse, France.
(7)Developmental and Stem Cell Biology Program, The Hospital for Sick Children, 
Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, 
The Hospital for Sick Children, Toronto, ON, Canada; Department of Medical 
Biophysics, University of Toronto, Toronto, ON, Canada.
(8)Department of Neurological surgery, University of Pittsburgh School of 
Medicine, and Cancer biology Program, UPMC Hillman Cancer center, Pittsburgh, 
PA, USA.
(9)Institut Curie, PSL Research University, Centre de Recherche, Laboratoire de 
Spectrométrie de Masse Protéomique, 26 rue d'Ulm, 75248 Paris, France.
(10)Institut Curie, INSERM U1331, MINES ParisTech, PSL Research University, 
Paris, France.
(11)Dipartimento di Ingegneria Enzo Ferrari, University of Modena and Reggio 
Emilia, Modena, Italy.
(12)Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao 
Tung University, Taipei, Taiwan.
(13)Division of Brain Tumor Translational Research, National Cancer Center 
Research Institute, Tokyo, Japan.
(14)Inovarion, Paris, France.
(15)Institut Curie, PSL University, CNRS UAR2016, INSERM US43, Université 
Paris-Saclay, Multimodal Imaging Center, 91400 Orsay, France.
(16)Department of Biochemistry and Molecular Biology, College of Medicine, 
University of Florida, Gainesville, FL 32610, USA; Center for Advanced Spatial 
Biomolecule Research, University of Florida, Gainesville, FL 32610, USA.
(17)Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies 
pour la Santé (MTS), MetaboHUB, Gif sur Yvette, France.
(18)Institut Curie, CurieCoreTech Metabolomics and Lipidomics platform, Paris, 
France.
(19)Institut Curie, Histology Facility, Orsay 91400, France.
(20)Institut Curie, Cytometry Platform, Orsay 91400, France.
(21)Institut Curie, PSL Research University, INSERM U1330/CNRS EMR 8001, 
Children's Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, 
Paris, France; Université Paris-Saclay, INSERM U1330/CNRS EMR 8001, Children's 
Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, Orsay, France; 
Université Paris Cité, France.
(22)The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for 
Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and 
Pathobiology, University of Toronto, Toronto, ON, Canada.
(23)Department of Pediatrics, Section of Hematology-Oncology, Baylor College of 
Medicine, Houston, TX, USA.
(24)INSERM U1330, Genomics and Development of Childhood Cancers Lab, Institut 
Curie, PSL University, SIREDO Oncology Center, Paris, France.
(25)Istituto Pasteur-Fondazione Cenci Bolognetti, University of Rome La 
Sapienza, 00161, Rome, Italy; Department of Molecular Medicine, University of 
Rome La Sapienza, 00161 Rome, Italy.
(26)Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for 
Cancer Research, Tokyo 135-8550, Japan.
(27)Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for 
Cancer Research, Tokyo 135-8550, Japan.
(28)Department of Neuro-oncology, Institute of Brain Science, Graduate School of 
Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.
(29)Department of Pediatric Oncology and Hematology, Saarland University Medical 
Center, Homburg, Germany.
(30)Department of Pediatric Neurosurgery, Rennes University Hospital, Rennes, 
France.
(31)Department of Pediatric Oncology, Rennes University Hospital, Rennes, 
France.
(32)SIREDO: Care, Innovation and Research for Children, Adolescents and Young 
Adults with Cancer, Institut Curie, 75005 Paris, France.
(33)Department of Pediatric Hemato-Oncology, National Center for Pediatrics, 
Centre Hospitalier du Luxembourg, Luxembourg City, Luxembourg.
(34)Department of Child and Adolescents Oncology, Gustave Roussy, Université 
Paris-Saclay, 94805 Villejuif, France.
(35)SIREDO: Care, Innovation and Research for Children, Adolescents and Young 
Adults with Cancer, Institut Curie, 75005 Paris, France; Institut Curie, INSERM 
U1330, Children's Oncology Research Unit (CONCERT), Université Paris Cité, 
Paris, France.
(36)Department of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, 
Sainte-Anne Hospital, Paris, France; UMR 1266, IMA-Brain, Institut de 
Psychiatrie et Neurosciences de Paris, Inserm, Paris, France.
(37)Department of Pediatric Neurosurgery, Necker Enfants Malades Hospital, APHP, 
Université Paris Cité, Paris, France.
(38)Unit of Somatic Genetics, Institut Curie, Paris, France.
(39)Heidelberg University, Faculty of Medicine, and Heidelberg University 
Hospital, Institute for Computational Biomedicine, Heidelberg, Germany.
(40)Heidelberg University, Faculty of Medicine, and Heidelberg University 
Hospital, Institute for Computational Biomedicine, Heidelberg, Germany; European 
Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), 
Wellcome Genome Campus, Cambridgeshire, UK.
(41)Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, 
PA, USA.
(42)Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of 
Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer 
Consortium (DKTK), Heidelberg, Germany; Princess Máxima Center for Pediatric 
Oncology, Utrecht, the Netherlands; National Center for Tumor Diseases (NCT) 
Heidelberg, Heidelberg, Germany; University Medical Center Utrecht (UMCU), 
Utrecht, the Netherlands.
(43)Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of 
Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer 
Consortium (DKTK), Heidelberg, Germany; National Center for Tumor Diseases (NCT) 
Heidelberg, Heidelberg, Germany; Department of Pediatric Oncology, Hematology 
and Immunology, Heidelberg University Hospital, Heidelberg, Germany.
(44)University of Pittsburgh, Department of Neurological Surgery, Pittsburgh, 
PA, USA.
(45)Université Toulouse, CNRS, Inserm, CRCT, Equipe labellisée Ligue Contre le 
Cancer, Toulouse, France.
(46)Institute of Brain Science, Brain Research Center, National Yang Ming Chiao 
Tung University, Taipei, Taiwan.
(47)Department of Child and Adolescents Oncology, Gustave Roussy, Université 
Paris-Saclay, 94805 Villejuif, France; INSERM U981, Molecular Predictors and New 
Targets in Oncology, University Paris-Saclay, Villejuif, France.
(48)Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, 
Inserm, CNRS, Equipe Labellisée LIGUE 2023, Toulouse, France; Labex TOuCAN, 
Toulouse, France. Electronic address: jean-emmanuel.sarry@inserm.fr.
(49)Department of Neurological surgery, University of Pittsburgh School of 
Medicine, and Cancer biology Program, UPMC Hillman Cancer center, Pittsburgh, 
PA, USA. Electronic address: micheala@pitt.edu.
(50)Division of Neurosurgery, Department of Surgery, Texas Children's Hospital, 
Houston, TX, USA; Neuro-oncology Research Program, Department of Pediatrics, 
Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA. 
Electronic address: michael.taylor@bcm.edu.
(51)Institut Curie, PSL Research University, INSERM U1330/CNRS EMR 8001, 
Children's Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, 
Paris, France; Université Paris-Saclay, INSERM U1330/CNRS EMR 8001, Children's 
Oncology Research Unit (CONCERT), Equipe Labellisée LIGUE 2024, Orsay, France. 
Electronic address: olivier.ayrault@curie.fr.

Medulloblastoma, the most common malignant brain tumor of childhood, exhibits 
significant biological complexity that demands deeper exploration. Here, we 
present a large multiomics dataset integrating data from 384 primary 
medulloblastoma patient samples across five omic layers: CpG methylome, 
transcriptome, proteome, phosphoproteome, and metabolome, paired with associated 
clinical metadata. Data integration revealed intertumoral heterogeneity of lipid 
metabolism across proteomic subtypes. Notably, while the MYC-FASN-SCD axis 
drives lipid biosynthesis, pathway inhibition elicits a compensatory escape 
mechanism in vivo through exogenous fatty acid uptake. Unexpectedly, we 
demonstrated that MYC triggers lipid storage, creating a unique dependency on 
lipid droplet-mitochondria communications to sustain tumor maintenance in vivo. 
Together, this comprehensive analysis reveals a targetable vulnerability 
downstream of MYC that constitutes a promising therapeutic approach to treat 
currently untreatable medulloblastoma subtypes.

Copyright © 2025. Published by Elsevier Inc.

DOI: 10.1016/j.ccell.2025.12.012
PMID: 41544627

Conflict of interest statement: Declaration of interests JSR reports funding 
from GSK, Pfizer and Sanofi and fees from Travere Therapeutics, Stadapharm, 
Owkin and Astex.